Currently, drugs targeting IL-1, including recombinant IL-1 receptor antagonist (anakinra), monoclonal IL-1β antibodies (canakinumab), and IL-1 traps (rilonacept) are approved for the treatment of inflammation-mediated diseases, including arthritis, gout, type 2 diabetes, and heart failure11. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.